UTHR vs. TEVA, BPMC, RETA, BBIO, BIIB, ALNY, BMRN, INCY, NBIX, and EXAS
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Teva Pharmaceutical Industries (TEVA), Blueprint Medicines (BPMC), Reata Pharmaceuticals (RETA), BridgeBio Pharma (BBIO), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), and Exact Sciences (EXAS). These companies are all part of the "medical" sector.
United Therapeutics (NASDAQ:UTHR) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
Teva Pharmaceutical Industries received 739 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 67.69% of users gave Teva Pharmaceutical Industries an outperform vote while only 62.06% of users gave United Therapeutics an outperform vote.
United Therapeutics has a net margin of 42.05% compared to Teva Pharmaceutical Industries' net margin of -2.88%. Teva Pharmaceutical Industries' return on equity of 37.33% beat United Therapeutics' return on equity.
United Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.
United Therapeutics currently has a consensus target price of $330.64, indicating a potential downside of 2.24%. Teva Pharmaceutical Industries has a consensus target price of $18.56, indicating a potential upside of 8.48%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than United Therapeutics.
In the previous week, United Therapeutics had 12 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 31 mentions for United Therapeutics and 19 mentions for Teva Pharmaceutical Industries. United Therapeutics' average media sentiment score of 0.92 beat Teva Pharmaceutical Industries' score of 0.74 indicating that United Therapeutics is being referred to more favorably in the media.
94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 12.5% of United Therapeutics shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
United Therapeutics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
United Therapeutics beats Teva Pharmaceutical Industries on 12 of the 18 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
